Miglustat is a substrate reduction therapy indicated for the oral treatment of patients with Gaucher disease.1 The mechanism of action of miglustat is presented in Figure 1. For further information on miglustat, please consult your local prescribing information.

Figure 1.
Mechanism of action of miglustat1,2

C-ANPROM/INT//7568; Date of preparation: September 2020

 
icon

DISEASE MANAGEMENT

Eliglustat

What is eliglustat?

Eliglustat is an oral substrate reduction therapy for Gaucher disease.

Read more
icon

DISEASE MANAGEMENT

Substrate reduction therapy

What substrate reduction therapies are available for Gaucher disease?

Two oral substrate reduction therapies are available for Gaucher disease: miglustat and eliglustat.

Read more
icon

DISEASE MANAGEMENT

Enzyme replacement therapy

What enzyme replacement therapies are available for Gaucher disease?

Three long-term enzyme replacement therapies are available for patients with Gaucher disease: imiglucerase, velaglucerase alfa and taliglucerase alfa.

Read more
icon

Register

Registration gives the benefit of site update emails and additional information on new education materials and events

Registration